The Government has taken various measures to realize the dream of ‘Make in India’ in pharmaceutical sector. In this direction, the Government had constituted a Committee under the chairmanship of Secretary, Department of Health Research. The mandate of this Committee was to carefully study the whole issue of Active Pharmaceutical Ingredients (APIs) of critical importance by identifying important APIs and then working out a package of interventions/concession required to build domestic production capabilities and examine the cost implications. Besides this, with a vision to catalyze and encourage quality, productivity and innovation in pharmaceutical sector and to enable the Indian pharmaceutical industry especially SMEs to play a leading role in a competitive global market, a scheme titled Cluster Development Programme for Pharma Sector (CDP-PS) is being implemented.
The Government has approved the National Pharmaceutical Pricing Policy-2012 and thereby has put in place a regulatory framework for pricing of drugs that would ensure availability of essential medicines at reasonable prices even while providing sufficient opportunity for innovation and competition to support the growth of industry, employment and shared economic well-being for all.
This information was given by the Minister of State for Chemicals & Fertilizers Shri Hansraj Gangaram Ahir in reply to an unstarred question by Shri Vinayak Bhaurao Raut and Shri Rahul Shewale in the Lok Sabha today.